Erythropoietic therapy for the treatment of anemia in patients with cancer: A valuable clinical and economic option

Current Medical Research and Opinion

Volumn 23, Issue 2, 2007, Pages 357-368

  Cornes, Paul ^a   Coiffier, Bertrand ^b   Zambrowski, Jean Jacques ^c,d  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b Hematology Department   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anemia; Blood transfusion; Cost effectiveness; Epoetin; Pharmacoeconomics

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; BREAST CANCER; BUDGET; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COMMERCIAL PHENOMENA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSE ESCALATION; ECONOMIC ASPECT; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; LUNG CANCER; MEDLINE; META ANALYSIS; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOLID TUMOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ABSENTEEISM; ANEMIA; BLOOD TRANSFUSION; BUDGETS; COST-BENEFIT ANALYSIS; DRUG COSTS; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEALTH CARE COSTS; HEMOGLOBINS; HUMANS; IRON; NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 33847339417     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167282     Document Type: Review

References (96)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
2. Barrett-Lee P, Bokemeyer C, Gascon P, et al; ECAS Advisory Board and Participating Centers. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 2005;10:743-57
3. Bosanquet N, Tolley K. Treatment of anaemia in cancer patients: implications for supportive care in the National Health Service Cancer Plan. Curr Med Res Opin 2003;19:643-50
4. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25:43-6
5. Hudis CA, Van Belle S, Chang J, Muenstedt K. rHuEPO and treatment outcomes: the clinical experience. Oncologist 2004;9(Suppl 5):55-69
6. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 2005;69(Suppl 2):2-7
7. Jacobsen PB, Garland LL, Booth-Jones M, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 2004;28:7-18
8. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001;91:2214-21
9. Di Maio M, Pisano C, Tambaro R, et al. The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. Front Biosci 2006;11:1585-90
10. Forbes JM, Anderson MD, Anderson GF, et al. Blood transfusion costs: a multicenter study. Transfusion 1991;31:318-23
11. Cavill I. Focus should be on improving patients' ability to make own blood. Br Med J 2002;325:655
12. Allain J-P. Transfusion risks of yesterday and of today. Transfus Clin Biol 2003;10:1-5
13. Zambrowski J-J. Réflexions médico-économiques sur la correction de l'anémie en onco-hématologie. Refl Med Oncol 2005;6:47-9
14. Crémieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000;18:2755-61
15. Agrawal SG, Davidson N, Walker M, et al. Assessing the total costs of blood delivery to hospital oncology and haematology patients. Curr Med Res Opin 2006;22:1903-9
16. Provan D. Better blood transfusion. BMJ 1999;318:1435-6
17. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001;47-61
18. Mortimer PP. Making blood safer. BMJ 2002;325:400-1
19. Sandler SG, Yu H, Rassai N. Risks of blood transfusion and their prevention. Clin Adv Hematol Oncol 2003;1:307-13
20. Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol 2006;132:13-24
21. Österborg A. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol 1998;15(Suppl 1):S47-9
22. Barrett-Lee PJ, Bailey NP, O'Brien ME, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82:93-7
23. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995;35:427-30
24. de Cock E, van Bellinghen L, Fabre-Guillevin E, et al. Assessing provider time and costs for red blood cell (RBC) transfusions in anaemia management of cancer patients using the activity-based costing (ABC) method in France. Hematol J 2003;56:0162 [abstract]
25. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16
26. Glaspy J, Bukowski R, Steinberg D, et al. The impact of therapy with epoetin alfa on clinical outcomes during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-34
27. Demetri GD, Kris M, Wade J, et al; Procrit Study Group. Quality-of-life benefits in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25
28. Littlewood TJ, Bajetta E, Nortier JW, et al; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
29. Fallowfield L, Gagnon D, Zagari M, et al; Epoetin Alfa Study Group. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving nonplatinum chemotherapy. Br J Cancer 2002;87:1341-53
30. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94
31. Boogaerts M, Coiffier B, Kainz C; Epoetin β QOL working group. Impact of epoetin β on quality of life in patients with malignant disease. Br J Cancer 2003;88:988-95
32. Hedenus M, Adriansson M, San Miguel J, et al; Darbepoetin Alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403
33. Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23:2597-605
34. O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005;5:439-46
35. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(Suppl 2):4-12
36. Barnett A, Birnbaum H, Crémieux PY, et al. The costs of cancer to a major employer in the United States: a case-control analysis. Am J Manag Care 2000;6:1243-51
37. Barnett A, Crémieux P-Y, Fendrick AM, et al. Anemia-related costs for cancer patients. J Manag Care Med 2002;6:20-8
38. Chaves PHM, Mody SH, Najib MM, et al. Anemia in the elderly is associated with increased healthcare costs and resource utilization. Blood 2003;102:2769 [abstract]
39. Penninx BW, Pahor M, Woodman RC, et al. Late-life anemia identifies persons at risk for mortality and hospitalization. Blood 2003;102:881 [abstract]
40. Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005;8:149-56
41. Nissenson AR, Wade S, Goodnough T, et al. Economic burden of anemia in an insured population. J Manag Care Pharm 2005;11:565-74
42. Jönsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004;22(Suppl 4):5-10
43. Greenhalgh T. How to read a paper: papers that tell you what things cost (economic analyses). BMJ 1997;315:596-9
44. Pirker R, Wiesenberger K, Pohl G, Minar W. Anemia in lung cancer: clinical impact and management. Clin Lung Cancer 2003;5:90-7
45. Barosi G, Marchetti M, Liberato NL. Cost effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anemia. Br J Cancer 1998;78:781-7
46. Cazzola M, Beguin Y, Kloczko J, et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-93
47. Vansteenkiste JF. Every 3 weeks dosing with darbepoetin alfa: a new paradigm in anaemia management. Cancer Treat Rev 2006;32(Suppl 2):S11-15
48. MacLaren R, Sullivan PW. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health 2005;8:105-16
49. Martin SC, Gagnon DD, Zhang L, et al. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Pharmacoeconomics 2003;21:1153-69
50. Antonadou D, Cardamakis E, Puglisi M, et al. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. Eur J Cancer 2001;37(Suppl 6):S144 [abstract 530]
51. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-15
52. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002:94:1211-20
53. Bamias A, Aravantinos G, Kalofonos C, et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003;64:102-10
54. Rosen FR, Haraf DJ, Kies MS, et al. Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003;9:1689-97
55. Machtay M, Pajak T, Suntharalingam M, et al. Definitive radiotherapy +/- erythropoietin for squamous cell carcinoma of the head and neck: preliminary report of RTOG 99-03. Int J Radiat Oncol Biol Phys 2004;60(Suppl 1):S132
56. Blohmer J-W, Wurschmidt F, Petry U, et al. Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Ann Oncol 2004;15 (Suppl 3):477PD [abstract]
57. Michael U, Jackisch C, Lenhard MS, et al. Epoetin alpha reduces red blood cell transfusions in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (P) and cyclophosphamide (C) (ETC). J Clin Oncol 2005;23:31s
58. Österborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow-up of a large randomized study. Br J Haematol 2005;129:206-9
59. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17
60. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60
61. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72
62. Vaupel P, Mayer A. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:992
63. Vaupel P, Dunst J, Engert A, et al. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia. Onkologie 2005;28:216-21
64. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14
65. Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23:6941-8
66. Crémieux P-Y, Finkelstein SN, Berndt ER, et al. Cost-effectiveness, quality-adjusted life-years and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 1999;16:459-72
67. Szucs TD, Boogaerts M, Coiffier B, Kainz C. Cost-effectiveness of epoetin beta in the management of cancer-related anaemia. Presented at the 6th Annual Congress of the European Haematology Association, Frankfurt, Germany 21-24 June. Hematol J 2001:192 [abstract]
68. Borget I, Tilleul P, Baud M, et al. Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis. Lung Cancer 2006;51:369-76
69. Rizzo JD, Lichtin AE, Woolf SH, et al; American Society of Clinical Oncology. American Society of Hematology. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107
70. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nat Clin Pract Oncol 2006;3:152-64
71. Cavill I, Auerbach M, Bailie GR, et al. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin 2006;22:731-7
72. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-7
73. Henry DH, Dahl NV, Auerbach M, et al; Ferrlecit Cancer Study Group. Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy - results of a multicenter, randomized trial. Blood 2004;104:3696 [abstract]
74. Agrawal SG, Lim C, Cavill I. Prospective targeted epoietin beta therapy for chemotherapy-associated anaemia achieves high response rates. Blood 2005;106:588 [abstract]
75. Bastit L, Gaede B, Yao B, et al. Darbepoetin alfa (DA) every 3 weeks (Q3W) +/- parenteral iron in patients (pts) with chemotherapy-induced anaemia (CIA). Ann Oncol 2006;17(9):ix293 [abstract 1015P]
76. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9
77. Hedenus M, Birgegård G, Näsman P, et al. Adjuvant intravenous iron therapy potentiates epoetin beta treatment in anemic, non iron-depleted patients with lymphoproliferative disorders: results of the NIFe study. Haematologica 2006;91(Suppl 1):365 [abstract 0996]
78. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994;84:1056-63
79. Glaspy J, Beguin Y. Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon®). Oncology 2005;69(Suppl 2):8-16
80. Waltzman R, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-50
81. Hedenus M, Hansen S, Taylor K, et al; Darbepoetin alfa 990114 Study Group. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86
82. Coiffier B. Epoetin once weekly in anaemic patients with cancer. Br J Haematol 2004;125:100-1
83. Morreale A, Plowman B, DeLattre M, et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004;20:381-95
84. Persson U, Borg S, Jansson S, et al. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs and hematologic response. Adv Ther 2005;22:208-24
85. Coiffier B, Milpied N, Facon T, Beris P. Epoetin beta (NeoRecormon) once weekly or three times weekly produces a rapid haemoglobin response in anaemic patients with lymphoproliferative malignancies. Hematol J 2004;5 (Suppl 2):551 [abstract]
86. Pujade-Lauraine E, Topham C. Once weekly treatment of anemia in patients with cancer: a comparative review of epoetins. Oncology 2005;68:122-9
87. Pujade-Lauraine E, Richard AJ, Sapède C. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alfa, epoetin beta and darbepoetin alfa use in routine clinical practice. Oncol Rep 2005;14:1037-44
88. Crémieux P, Greenberg P, Piech CT. Epoetin alfa is more effective and less costly relative to darbepoetin alfa in lung cancer patients receiving treatment for chemotherapy-induced anemia. Proc Am Soc Clin Oncol 2003;22:559 [abstract 2248]
89. Mark TL, McKenzie RS, Piech CT. Better early and overall hematologic outcomes and lower drug cost with epoetin alfa (EPO) compared with darbepoetin alfa (DARB). Blood 2003;102:5772 [abstract]
90. van Hout BA, Gagnon DD. The cost-effectiveness of epoetin alfa (EPREX) and darbepoetin alfa (ARANESP) in the treatment of chemotherapy-related anemia. Hematol J 2004;5(Suppl 2):S176 [abstract 512]
91. Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, et al. The cost effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia. Curr Med Res Opin 2005;21:1677-82
92. Rosberg JH, Ben-Hamadi R, Crémieux PY, et al. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-induced anaemia. Clin Drug Invest 2005;25:33-48
93. Killian AD, Gupta V, Goetz AE. Cost analysis of erythropoietic- stimulating therapy dosing in oncology inpatients. Ann Pharmacother 2006;40:421-6
94. Hornberger J. Costs of once weekly treatment with epoetin in anemic patients with hematological malignancies. Blood 2003;102:3776 [abstract]
95. Reichardt B. Evidence-based, novel comparison between epoetin alfa, epoetin beta and darbepoetin alfa based on drug use, efficacy and treatment costs in daily oncological use. Hematol J 2004;5(Suppl 2):S177 [abstract 513]
96. Malonne H. Cost evaluation of erythropoiesis stimulating agents in the treatment of platinum chemotherapy-induced anaemia. Presented at the 20th Annual meeting of the Belgian Hematology Society, Genval, Belgium. 28-29 January 2005